{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Interstitial+Lung+Disease+With+Systemic+Sclerosis", "query": { "condition": "Interstitial Lung Disease With Systemic Sclerosis" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 27, "total_pages": 3, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Interstitial+Lung+Disease+With+Systemic+Sclerosis&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-05-22T05:49:41.464Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT02597933", "title": "A Trial to Compare Nintedanib With Placebo for Patients With Scleroderma Related Lung Fibrosis", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Scleroderma, Systemic" ], "interventions": [ { "name": "Nintedanib", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Boehringer Ingelheim", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 580, "start_date": "2015-11-12", "completion_date": "2018-11-28", "has_results": true, "last_update_posted_date": "2019-12-13", "last_synced_at": "2026-05-22T05:49:41.464Z", "location_count": 44, "location_summary": "Birmingham, Alabama • Los Angeles, California • Sacramento, California + 36 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Los Angeles", "state": "California" }, { "city": "Sacramento", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Stanford", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT02597933" }, { "nct_id": "NCT02745145", "title": "Abituzumab in SSc-ILD", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Systemic Sclerosis-associated Interstitial Lung Disease" ], "interventions": [ { "name": "Abituzumab 1500 mg", "type": "DRUG" }, { "name": "Abituzumab 500 mg", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "EMD Serono Research & Development Institute, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "18 Years to 75 Years" }, "enrollment_count": 24, "start_date": "2016-05-31", "completion_date": "2018-05-30", "has_results": true, "last_update_posted_date": "2019-06-18", "last_synced_at": "2026-05-22T05:49:41.464Z", "location_count": 18, "location_summary": "Los Angeles, California • Farmington, Connecticut • Washington D.C., District of Columbia + 12 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Farmington", "state": "Connecticut" }, { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Orlando", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT02745145" }, { "nct_id": "NCT05455437", "title": "Monitoring and Evaluation Study of Project ECHO for ILD", "overall_status": "UNKNOWN", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Interstitial Lung Diseases" ], "interventions": [], "intervention_types": [], "sponsor": "Pulmonary Care and Research Collaborative Limited", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": null, "sex": "ALL", "summary": "Not listed" }, "enrollment_count": 200, "start_date": "2022-07", "completion_date": "2024-03", "has_results": false, "last_update_posted_date": "2022-07-13", "last_synced_at": "2026-05-22T05:49:41.464Z", "location_count": 1, "location_summary": "Boston, Massachusetts", "locations": [ { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT05455437" }, { "nct_id": "NCT03313180", "title": "A Trial to Evaluate the Safety of Long Term Treatment With Nintedanib in Patients With Scleroderma Related Lung Fibrosis", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Lung Diseases, Interstitial" ], "interventions": [ { "name": "Nintedanib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Boehringer Ingelheim", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 444, "start_date": "2017-11-27", "completion_date": "2023-01-25", "has_results": true, "last_update_posted_date": "2024-02-20", "last_synced_at": "2026-05-22T05:49:41.464Z", "location_count": 39, "location_summary": "Birmingham, Alabama • Los Angeles, California • Sacramento, California + 31 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Los Angeles", "state": "California" }, { "city": "Sacramento", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Stanford", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT03313180" }, { "nct_id": "NCT06195072", "title": "Platform Clinical Study for Conquering Scleroderma", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Interstitial Lung Disease Due to Systemic Disease", "Scleroderma" ], "interventions": [ { "name": "Amlitelimab", "type": "DRUG" }, { "name": "BI 1015550 (Nerandomilast)", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Scleroderma Research Foundation, Inc.", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 400, "start_date": "2024-04-15", "completion_date": "2026-11", "has_results": false, "last_update_posted_date": "2026-02-04", "last_synced_at": "2026-05-22T05:49:41.464Z", "location_count": 34, "location_summary": "Birmingham, Alabama • Los Angeles, California • Palo Alto, California + 23 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Palo Alto", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT06195072" }, { "nct_id": "NCT03726398", "title": "CompRehensive Phenotypic Characterization of Patients With Scleroderma-Associated ILD and PH", "overall_status": "WITHDRAWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2", "PHASE3" ], "conditions": [ "Interstitial Lung Disease", "Scleroderma", "Pulmonary Hypertension" ], "interventions": [ { "name": "Opsumit 10 Mg Tablet", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Franz Rischard, DO", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 0, "start_date": "2018-09-01", "completion_date": "2020-08-03", "has_results": false, "last_update_posted_date": "2025-02-20", "last_synced_at": "2026-05-22T05:49:41.464Z", "location_count": 1, "location_summary": "Tucson, Arizona", "locations": [ { "city": "Tucson", "state": "Arizona" } ], "official_url": "https://clinicaltrials.gov/study/NCT03726398" }, { "nct_id": "NCT05450276", "title": "Patient-Reported Outcome Study of Project ECHO for ILD", "overall_status": "UNKNOWN", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Interstitial Lung Disease" ], "interventions": [], "intervention_types": [], "sponsor": "Pulmonary Care and Research Collaborative Limited", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 56, "start_date": "2022-07", "completion_date": "2024-03", "has_results": false, "last_update_posted_date": "2022-07-08", "last_synced_at": "2026-05-22T05:49:41.464Z", "location_count": 1, "location_summary": "Boston, Massachusetts", "locations": [ { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT05450276" }, { "nct_id": "NCT05270668", "title": "Phase 2 Safety and Efficacy Study of Tulisokibart (MK-7240/PRA023) in Subjects With Systemic Sclerosis Associated With Interstitial Lung Disease (SSc-ILD) (MK-7240-007)", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Diffuse Cutaneous Systemic Sclerosis", "Interstitial Lung Disease" ], "interventions": [ { "name": "Tulisokibart", "type": "DRUG" }, { "name": "Companion diagnostic ( CDx)", "type": "DIAGNOSTIC_TEST" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG", "DIAGNOSTIC_TEST" ], "sponsor": "Prometheus Biosciences, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 154, "start_date": "2022-03-29", "completion_date": "2029-07-31", "has_results": false, "last_update_posted_date": "2026-05-18", "last_synced_at": "2026-05-22T05:49:41.464Z", "location_count": 20, "location_summary": "Phoenix, Arizona • Los Angeles, California • Palo Alto, California + 14 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Palo Alto", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT05270668" }, { "nct_id": "NCT06329401", "title": "A Study Evaluating the Safety and Efficacy of Inhaled AP01 in Participants With Progressive Pulmonary Fibrosis", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Pulmonary Fibrosis", "Progressive Pulmonary Fibrosis", "Pulmonary Fibrosis Secondary to Systemic Sclerosis", "Pulmonary Fibrosis, Interstitial Lung Disease", "Interstitial Lung Disease", "Interstitial Lung Disease Due to Connective Tissue Disease (Disorder)", "Interstitial Lung Disease in Patients With Rheumatoid Arthritis", "Interstitial Lung Disease With Progressive Fibrotic Phenotype in Diseases Classified Elsewhere", "Hypersensitivity Pneumonitis", "Interstitial Lung Disease With Systemic Sclerosis" ], "interventions": [ { "name": "AP01", "type": "DRUG" }, { "name": "Placebo", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "Avalyn Pharma Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 375, "start_date": "2024-04-03", "completion_date": "2027-06", "has_results": false, "last_update_posted_date": "2026-04-06", "last_synced_at": "2026-05-22T05:49:41.464Z", "location_count": 59, "location_summary": "Birmingham, Alabama • Scottsdale, Arizona • Los Angeles, California + 45 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Scottsdale", "state": "Arizona" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT06329401" }, { "nct_id": "NCT05878717", "title": "A Study of the Efficacy and Safety of Belimumab in Adults With Systemic Sclerosis Associated Interstitial Lung Disease", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2", "PHASE3" ], "conditions": [ "Systemic Sclerosis Associated Interstitial Lung Disease", "Scleroderma, Systemic" ], "interventions": [ { "name": "Belimumab", "type": "BIOLOGICAL" }, { "name": "Placebo", "type": "OTHER" } ], "intervention_types": [ "BIOLOGICAL", "OTHER" ], "sponsor": "GlaxoSmithKline", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 300, "start_date": "2023-09-13", "completion_date": "2029-07-12", "has_results": false, "last_update_posted_date": "2026-01-12", "last_synced_at": "2026-05-22T05:49:41.464Z", "location_count": 24, "location_summary": "Phoenix, Arizona • Scottsdale, Arizona • Tucson, Arizona + 17 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Scottsdale", "state": "Arizona" }, { "city": "Scottsdale", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT05878717" } ] }